The Use of Phospholipids to Make Pharmaceutical Form Line Extensions
Review by Peter van Hoogevest, Harry Tiemessen, Josbert M. Metselaar, Simon Drescher, and Alfred Fahr, 2021, Eur. J. Lipid Sci. Technol., 2000297.
This review describes the use ofphospholipid excipients to make Pharmaceutical Form (Dosage Form) Line Extensions ofexisting drugs as part ofa Product Life Cycle Management. Product examples and development candidates, which show the versatility ofphospholipids as key excipients in formulations to develop line extension drug products for any administration route by reformulating existing products, are provided. The resulting patented products enable the application ofa drug substance for another administration route or show an increased efficacy and/or reduced toxicity of the formulated drug substances, or enable a more convenient use, through reduction ofdosing frequency, or adapt a product for regulatory requirements for specific patient populations. Parenteral line extensions for lipophilic drugs using non-toxic phospholipid-based solubilising formulations are clearly an alternative to products with solubilising synthetic detergents with the risk for allergic and anaphylactic reactions. This review draws the attention to academic and industrial formulation scientist to consider using phospholipid excipients to reformulate existing products to improve the product properties by an active product life cycle management. Phospholipids are suitable for this purpose because they are biocompatible, biodegradable, non-toxic, and available at large scale and ofpharmaceutical grade. Besides, they are well known to regulatory authorities.